Florida Trust Wealth Management Co Sells 4,244 Shares of Johnson & Johnson $JNJ

Florida Trust Wealth Management Co lessened its position in Johnson & Johnson (NYSE:JNJ) by 1.1% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 373,794 shares of the company’s stock after selling 4,244 shares during the quarter. Johnson & Johnson makes up about 2.0% of Florida Trust Wealth Management Co’s portfolio, making the stock its 11th biggest position. Florida Trust Wealth Management Co’s holdings in Johnson & Johnson were worth $69,309,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in JNJ. Tred Avon Family Wealth LLC acquired a new stake in shares of Johnson & Johnson in the third quarter valued at approximately $5,137,000. FAS Wealth Partners Inc. grew its position in Johnson & Johnson by 2.4% in the third quarter. FAS Wealth Partners Inc. now owns 41,848 shares of the company’s stock valued at $7,760,000 after purchasing an additional 980 shares in the last quarter. Donoghue Forlines LLC increased its stake in Johnson & Johnson by 119.4% in the 3rd quarter. Donoghue Forlines LLC now owns 20,816 shares of the company’s stock valued at $3,860,000 after buying an additional 11,328 shares during the last quarter. CFC Planning Co LLC lifted its position in Johnson & Johnson by 5.9% during the 3rd quarter. CFC Planning Co LLC now owns 19,357 shares of the company’s stock worth $3,589,000 after buying an additional 1,077 shares in the last quarter. Finally, Resonant Capital Advisors LLC boosted its stake in shares of Johnson & Johnson by 5.6% during the 3rd quarter. Resonant Capital Advisors LLC now owns 31,647 shares of the company’s stock worth $5,868,000 after buying an additional 1,686 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Daiwa America raised Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 20th. Wall Street Zen cut Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Saturday. Sanford C. Bernstein increased their price objective on Johnson & Johnson from $193.00 to $208.00 and gave the company a “market perform” rating in a report on Friday, January 9th. Weiss Ratings restated a “buy (b)” rating on shares of Johnson & Johnson in a report on Friday, October 31st. Finally, Scotiabank began coverage on shares of Johnson & Johnson in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $230.00 price target for the company. Four research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $213.33.

Johnson & Johnson Stock Performance

JNJ opened at $218.09 on Wednesday. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 12-month low of $141.50 and a 12-month high of $220.11. The business has a 50 day moving average of $206.92 and a 200-day moving average of $188.05. The stock has a market cap of $525.43 billion, a price-to-earnings ratio of 21.05, a PEG ratio of 2.25 and a beta of 0.34.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s payout ratio is 50.19%.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Positive Phase 3 results for CAPLYTA (major psychiatric drug) showed stronger remission outcomes, lifting biotech/pharma sentiment around JNJ. CAPLYTA Shows Stronger Remission Results in Phase 3 MDD Data, JNJ Says
• Positive Sentiment: Robotic surgery business and a recent regulatory submission are cited as supporting JNJ’s dividend-growth outlook, reinforcing income-investor interest. Robotic surgery fuels Johnson & Johnson dividend growth outlook
• Positive Sentiment: High-profile bullish coverage: Jim Cramer has been increasingly positive on JNJ, noting strength in the cancer portfolio and framing JNJ as a core holding — a boost to retail sentiment. Jim Cramer Says He Was Wrong for Selling Johnson & Johnson for the Charitable Trust
• Positive Sentiment: Market commentary points to JNJ nearing a 52-week high as CAPLYTA data and earnings momentum lift near-term upside expectations. Johnson & Johnson Near 52-Week High As CAPLYTA Data Boosts Sentiment
• Neutral Sentiment: Analyst previews ahead of Q4 (earnings due Jan 21) are broadly constructive — core pharma and MedTech strength cited, but Q4/2026 guidance is the key near-term catalyst. Johnson & Johnson Q4 preview: Strength in core portfolio keeps analysts bullish
• Neutral Sentiment: Coverage pieces detail ways to generate income from JNJ shares and options ahead of earnings — increased retail/options activity could amplify intraday moves. How To Earn $500 A Month From Johnson & Johnson Stock Ahead Of Q4 Earnings
• Neutral Sentiment: Index/sector coverage notes JNJ’s MedTech reach on Dow-related indices — supportive for passive flows but not an immediate price catalyst. Johnson & Johnson (NYSE:JNJ) Dow Jones Index Medical Technology Reach
• Negative Sentiment: Broader market “risk-off” (Davos/Trump headlines) pressured US equities today, which weighed on JNJ despite company-specific gains. Markets Switch to “Risk-Off” Ahead of Trump at Davos
• Negative Sentiment: Analysts and previews flag near-term risks: Stelara biosimilar competition and China headwinds could pressure growth and margin recovery in 2026. Should You Buy, Sell or Hold J&J Stock Ahead of Q4 Results?
• Negative Sentiment: Outlook risk: commentary warns 2026 guidance will be a big test for JNJ’s valuation — missed targets or cautious guidance could trigger a pullback. Johnson & Johnson’s $10 Billion Test: 2026 Outlook Could Make Or Break JNJ Heading Into Q4

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.